Back to Atlas
BSemi-durableStandard research/education caution
CMP-0171
Approved/used in some regions; not FDA-approved
Bemethyl / Bemitil
Ergogenic / Anti-fatigue
May improve work capacity, fatigue resistance, and heat/hypoxia resilience
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Small molecule actoprotector
- Primary mechanism
- Antihypoxic, antioxidant, protein-synthesis and metabolic adaptation mechanisms
- Primary market use
- Anti-fatigue / performance
Pharmacology
- Molecular weight (Da)
- 178.26 parent; ~259.17 HBr
- Oral bioavailability
- Oral; quantitative F not well established
- Half-life
- Not clearly established; metabolites detectable up to 58-78 h
- Route tags
- Oral
- Evidence level
- Human/Regional use
- Clinical status
- Approved/used in some regions; not FDA-approved
- Value-for-money score
- 7 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Potentially good value due oral route and low cost, but Western clinical validation is limited